Vyome Biosciences , a clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that it administered the first in-human dose of its lead candidate VB 1953 in its Phase 1 clinical trial being conducted in the United States to treat patients with moderate to severe facial acne.
This open-label study is designed to evaluate the safety, tolerability and pharmacokinetics of VB 1953, a topically administered gel developed to treat patients with moderate to severe acne. According to the study protocol, VB 1953 will be administered twice daily for a treatment period of 14 days following a 30-day screening period. The clinical study, which is being conducted by a CRO (Therapeutics Inc.), continues to enroll patients at a single clinical site; Therapeutics Clinical Research, in San Diego, CA.
“Microbial resistance often limits the effectiveness of treatment of moderate to severe acne. We are looking forward to evaluating VB 1953 in this patient population,” said Investigator Neal Bhatia, MD, of Therapeutics Clinical Research.
"One-third of patients with moderate to severe acne do not respond to available treatment options which is due, at least in part, to microbial resistance. We believe VB 1953 can address this significant unmet need. This milestone is an important step in that direction,” said Venkateswarlu Nelabhotla (N. Venkat), Co-founder and Chief Executive Officer of Vyome Biosciences.
Approximately 240 million people are diagnosed with moderate to severe acne globally, and studies show that nearly 40 percent of these patients are affected by antibiotic resistance. According to the American Academy of Dermatology, acne represents the most common skin disease, affecting 40-50 million people in the United States alone, including 85 percent of teenagers.
About VB 1953
VB 1953 is Vyome Biosciences’ lead program focused on the treatment of antibiotic resistant acne. It is currently in evaluation in U.S. FDA Phase 1 clinical studies. As a first-in-class topical treatment option, VB 1953 has bactericidal properties, addresses antibiotic resistance and also exerts an anti-inflammatory effect. Vyome has developed the product using micro-technology gel system that optimizes skin deposition and minimizes systemic exposure.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage specialty bio-pharmaceutical company, which has novel platform technologies and a deep pipeline that addresses drug-resistant skin opportunistic pathogens such as antibiotic resistant acne. Vyome’s lead program VB 1953, which targets the unmet need of antibiotic resistant acne, is currently under evaluation in U.S. FDA Phase 1 clinical studies. Vyome also has a deep pipeline of preclinical new chemical entities, unique in their ability to overcome the development of resistance based on patented Dual Action Rational Therapeutics (DARTs) technology. In addition, Vyome has developed clinically proven antifungal products based on an innovative technology platform, Molecular Replacement Therapy (MRT™). Vyome has assembled a world-class team of scientific experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005368/en/Business Wire
Last updated on: 31/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.